Ten Years After – Looking Back At A Biotech Boom...

Introduction There have historically been overlapping biotech booms and IPO windows, the three most recent boom/windows being 1995-1996, 1999-2001 and 2003-2005. Each of these boom/windows was impacted by positive external market forces, with the last two benefiting from the dot-com bubble and the post-9/11 market bounce, respectively. The driving factors within biotech have been different for each boom/window: 1995-1996 was...

The Burrill Report – Canadian Edition, April...

Canada’s biotech stocks sizzled in the first quarter as they racked up impressive gains. The Burrill Canadian Biotech Index jumped 12 percent during the period. This is good news for the sector, which has languished for over three years. Low valuations have hampered the ability of public biotech companies to raise capital. The improving capital markets in Canada and the United States have helped bolster Toronto’s main...

ONTARIO’S LIFE SCIENCES COMMERCIALIZATION STRATE...

…But today our industry is being challenged by increased global competition from established and emerging life sciences jurisdictions, as well as by difficult economic conditions that include tight credit and market volatility. To compete successfully in the global marketplace, we know that our industry needs to continue to attract and nurture great scientific minds, increase collaboration among all the players –...

Q1 2010 Canadian Healthcare Review...

Financing Public Canadian healthcare companies completed equity and convertible debt financings during this quarter for total gross proceeds of $236.0 million (Appendix 1). The largest financing in the sector was the only financing in the Services group, $86.3 million by Extendicare. The largest financing in the Therapeutics group was $34.5 million from a rights offering by Wex Pharmaceuticals, with 97.6% of the shares being...

Discussion Notes: Quebec/Ontario Bioscience CEO Di...

What Quebec/Ontario Government funded programs are most effective? First and foremost, as entrepreneurs our duty is to create shareholder wealth with products and services the marketplace demands.  This cannot be substituted with or diverted by any government funding program. Quebec:  Tax holidays for key employees; tax exemption for new products developed in Quebec Quebec’s SR&ED tax credit regime is a...

OBIO Releases Biotechnology Industry Consultation ...

OBIO Biotechnology Industry Consultation Report November 2009 (Download PDF / View Online) Executive Summary The Ontario government has recognized the importance of the emerging knowledge economy to the province’s future prosperity. The biotechnology industry is an important part of a knowledge economy. The confluence of external and internal factors has converged to create an unprecedented crisis in this sector. The...

Review of the Canadian Healthcare Sector in 2009 b...

Public Canadian healthcare companies operate in a complex, challenging and constantly changing global environment. In 2009, some companies celebrated success, most focused on survival and a few did not make it. In this review, we will look at some of the environmental changes and company-specific events of 2009 which characterize this challenging year and will impact the future of this sector.The sector raised a total of...

The Canadian Blueprint: Beyond Moose and Mountains...

Biotechnology is creating products and processes that improve our quality of life. Just as importantly, biotechnology is also creating high-quality jobs for Canadians in every part of the country; rewarding, knowledge economy jobs. No matter where we live, we all have a stake in the bio-based economy. The “Canadian Blueprint” is a strategy that will enable us to take full advantage of all the opportunities biotechnology...